Human telomerase RNA degradation by 2′-5′-linked oligoadenylate antisense chimeras in a cell-free system, cultured tumor cells, and murine xenograft models

Oligonucleotides

Volumn 16, Issue 3, 2006, Pages 225-238

  Paranjape, Jayashree M ^a   Xu, Da ^b   Kushner, David M ^a,c   Okicki, James ^d   Lindner, Daniel J ^e   Cramer, Hagen ^d,f   Silverman, Robert H ^a   Leaman, Douglas W ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

^c University of Wisconsin Health   (United States)

^d Ridgeway Biosciences   (United States)

^e TAUSSIG CANCER INSTITUTE   (United States)

^f Girindus America Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLIC ACID; ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA INTERFERON; GENOMIC RNA; HOLOENZYME; RBI 008; RBI 009; RBI 010; RBI 011; RBI 013; RBI 014; RBI 043; RBI 254; RBI 256; RBI 331; RBI 801; RIBONUCLEASE; RIBONUCLEASE L; RIBONUCLEOPROTEIN; SINGLE STRANDED RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL FREE SYSTEM; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL VIABILITY; CHIMERA; CONTROLLED STUDY; DOSE RESPONSE; DRUG DESIGN; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME SUBUNIT; FEMALE; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; GENETIC MANIPULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION; RECOMBINANT DNA TECHNOLOGY; RNA DEGRADATION; TELOMERE; TREATMENT RESPONSE; TUMOR CELL CULTURE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL-FREE SYSTEM; ENDORIBONUCLEASES; FEMALE; HUMANS; MICE; OLIGORIBONUCLEOTIDES, ANTISENSE; RNA; TELOMERASE; TRANSPLANTATION, HETEROLOGOUS;

MURINAE; MUS MUSCULUS;

EID: 33751112281     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2006.16.225     Document Type: Article

References (60)

1. AKIYAMA, M., HIDESHIMA, T., SHAMMAS, M.A., HAYASHI, T., HAMASAKI, M., TAI, Y.T., RICHARDSON, P., GRYAZNOV, S., MUNSHI, N.C., and ANDERSON, K.C. (2003). Effects of oligonucleotide N3′ → P5′ thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 63, 6187-6194.
2. ASAI, A., OSHIMA, Y., YAMAMOTO, Y., UOCHI, T.A., KUSAKA, H., AKIMAGA, S., YAMASHITA, Y., PONGRACZ, K., PRUZAN, R., WUNDER, E., PIATYSZEK, M., LI, S., CHIN, A.C., HARLEY, C.B., and GRYAZNOV, S. (2003). A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 63, 3931-3939.
3. BLASCO, M.A., FUNK, W., VILLEPONTEAU, B., and CREIDER, C.W. (1995). Functional characterization and developmental regulation of mouse telomerase RNA. Science 269, 1267-1270.
4. BODNAR, A.G., OUELLETTE, M., FROLKIS, M., HOLT, S.E., CHIU, C.P., MORIN, G.B., HARLEY, C.B., SHAY, J.W., LICHTSTEINER, S., and WRIGHT, W.E. (1998). Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349-352.
5. BOUSSIF, O., LEZOUALC'H, F., ZANTA, M.A., MERGNY, M.D., SCHERMAN, D., DEMENEIX, B., and BEHR, J.P. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc. Natl. Acad. Sci. U.S.A. 92, 7297-7301.
6. CECH, T.R. (2004). Beginning to understand the end of the chromosome. Cell 116, 273-279.
7. CHEMIN, I., MORADPOUR, D., WIELAND, S., OFFENSPERGER, W.B., WALTER, E., BEHR, J.P., and BLUM, H.E. (1998). Liver directed gene transfer: A linear polyethlenimine derivative mediates highly efficient DNA delivery to primary hepatocytes in vitro and in vivo. J. Viral. Hepat. 5, 369-375.
8. CIRINO, N.M., LI, G., XIAO, W., TORRENCE, P.F., and SILVERMAN, R.H. (1997). Targeting RNA decay with 2′,5′ oligoadenylate-antisense in respiratory syncytial virus-infected cells. Proc. Natl. Acad. Sci. U.S.A. 94, 1937-1942.
9. COUNTER, C.M. (1996). The roles of telomeres and telomerase in cell life span. Mutat. Res. 366, 45-63.
10. CROOKE, S.T. (1992). Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol. 32, 329-376.
11. DE LANGE, T., and DEPINHO, R.A. (1999). Unlimited mileage from telomerase? Science 283, 947-949.
12. DHEUR, S., DIAS, N., VAN AERSCHOT, A., HERDEWIJN, P., BETTINGER, T., REMY, J.S., HELENE, C., and SAISON-BEHMOARAS, E.T. (1999). Polyethylenimine but not cationic lipid improves antisense activity of 3′-capped phosphodiester oligonucleotides. Antisense Nucleic Acid Drug Dev. 9, 515-525.
13. FENG, J., FUNK, W.D., WANG, S.S., WEINRICH, S.L., AVBLION, A.A., CHIU, C.P., ADAMS, R.R., CHANG, E., ALLSOPP, R.C., YU, J., LE, S., WEST, M.D., HARLEY, C.B., ANDREWS, W.H., GREIDER, C.W., and VILLEPONTEAU, B. (1995). The RNA component of human telomerase. Science 269, 1236-1241.
14. FOLINI, M., and ZAFFARONI, N. (2005). Targeting telomerase by antisense-based approaches: Perspectives for new anti-cancer therapies. Curr. Pharm. Des. 11, 1105-1117.
15. GEWIRTZ, A.M., SOKOL, D.L., and RATAJCZAK, M.Z. (1998). Nucleic acid therapeutics: State of the art and future prospects. Blood 92, 712-736.
16. GREIDER, C.W. (1996). Telomere length regulation. Annu. Rev. Biochem. 65, 337-365.
17. GUZAEV, A., and MANOHARAN, M. (2001). Novel reagents for terminal phosphorylation and thiophosphorylation of synthetic oligonucleotides. Tetrahedron Lett. 42, 4769-4773.
18. GUZAEV, A., SALO, H., AZHAYEV, A., and LONNBERG, H. (1995). A new approach for chemical phosphorylation of oligonucleotides at the 5′-terminus. Tetrahedron 51, 9375-9384.
19. HAHN, W.C., STEWART, S.A., BROOKS, M.W., YORK, S.G., EATON, E., KURACHI, A., BEIJERSBERGEN, R.L., KNOLL, J.H., MEYERSON, M., and WEINBERG, R.A. (1999). Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 5, 1164-1170.
20. HAMILTON, S.E., PITTS, A.E., KATIPALLY, R.R., JIA, X., RUTTER, J.P., DAVIES, B.A., SHAY, J.W., WRIGHT, W.E., and COREY, D.R. (1997). Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning. Biochemistry 36, 11873-11880.
21. HEALY, K.C. (1995). Telomere dynamics and telomerase activation in tumor progression: Prospects for prognosis and therapy. Oncol. Res. 7, 121-130.
22. KIM, M.M., RIVERA, M.A., BOTCHKINA, I.L., SHALABY, R., THOR, A.D., and BLACKBURN, E.H. (2001). A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 98, 7982-7987.
23. KOGA, S., KONDO, Y., KOMATA, T., and KONDO, S. (2001). Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA. Gene Ther. 8, 654-658.
24. KOMATA, T., KONDO, Y., KOGA, S., KO, S.C., CHUNG, L.W., and KONDO, S. (2000). Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53. Gene Ther. 7, 2071-2079.
25. KONDO, S., KONDO, Y., GUIYING, L., SILVERMAN, R.H., and COWELL, J.K. (1998a). Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 16, 3323-3330.
26. KONDO, S., TANAKA, Y., and KONDO, Y. (1998b). Antisense telomerase treatment: Induction of two distinct pathways, apoptosis and differentiation. FASEB J. 12, 801-811.
27. KONDO, Y., KOGA, S., KOMATA, T., and KONDO, S. (2000). Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Oncogene 19, 2205-2211.
28. KONDO, Y., KOMATA, T., and KONDO, S. (2001). Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas. Int. J. Oncol. 18, 1287-1292.
29. KUSHNER, D.M., PARANJAPE, J.M., BANDYOPADHYAY, B., CRAMER, H., LEAMAN, D.W., KENNEDY, A.W., SILVERMAN, R.H., and COWELL, J.K. (2000). 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells. Gynecol. Oncol. 76, 183-192.
30. LANGFORD, L.A., PIATYSZEK, M.A., XU, R., SCHOLD, S.C., and SHAY, J.W. (1995). Telomerase activity in human brain tumours. Lancet 346, 1267-1268.
31. LEAMAN, D.W., and CRAMER, H. (1999). Controlling gene expression with 2-5 A antisense. Methods 18, 252-265.
32. LEAMAN, D.W., LONGANO, F.J., OKICKI, J.R., SOIKE, K.F., TORRENCE, P.P., SILVERMAN, R.H., and CRAMER, H. (2002). Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense. Virology 292, 70-77.
33. LECCHI, P., LE, H.M., and PANNELL, L.K. (1995). 6-Aza-2-thiomymine: A matrix for MALDI spectra of oligonucleotides. Nucleic Acids Res. 23, 1276-1277.
34. LI, G., XIAO, W., and TORRENCE, P.F. (1997). Synthesis and properties of second-generation 2-5A-antisense chimeras with enhanced resistance to exonucleases. J. Med. Chem. 40, 2959-2966.
35. MAITRA, R.K., LI, G., XIAO, W., DONG, B., TORRENCE, P.F., and SILVERMAN, R.H. (1995). Catalytic cleavage of an RNA target by 2-5A antisense and RNase L. J. Biol. Chem. 270, 15071-15075.
36. MARAN, A., MAITRA, R.K., KUMAR, A., DONG, B., XIAO, W., LI, G., WILLIAMS, B.R., TORRENCE, P.F., and SILVERMAN, R.H. (1994). Blockage of NF-κB signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science 265, 789-792.
37. MARAN, A., WALLER, C.F., PARANJAPE, J.M., LI, G., XIAO, W., ZHANG, K., KALAYCIO, M.E., MAITRA, R.K., LICHTIN, A.E., BRUGGER, W., TORRENCE, P.P., and SILVERMAN, R.H. (1998). 2′,5′-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells. Blood 92, 4336-4343.
38. MUKAI, S., KONDO, Y., KOGA, S., KOMATA, T., BARNA, B.P., and KONDO, S. (2000). 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res. 60, 4461-4467.
39. MUNROE, S.H. (1997). Antisense Technology: A Practical Approach. C. Lichetenstein and W. Nellen, eds. (IRL Books/Oxford University Press, Oxford), pp. 157-172.
40. NAKAMURA, T.M., MORIN, G.B., CHAPMAN, K.B., WEINRICH, S.L., ANDREWS, W.H., LINGNER, J., HARLEY, C.B., and CECH, T.R. (1997). Telomerase catalytic subunit homologs from fission yeast and human. Science 277, 955-959.
41. NORTON, J.C., PIATYSZEK, M.A., WRIGHT, W.E., SHAY, J.W., and COREY, D.R. (1996). Inhibition of human telomerase activity by peptide nucleic acids. Nat. Biotechnol. 4, 615-619
42. PAWLAK, W., ZOLNIEREK, J., SAROSIEK, T., and SZCZYLIK, C. (2000). Antisense therapy in cancer. Cancer Treat. Rev. 26, 333-350.
43. PERSIDIS, A. (1999). Antisense therapeutics. Nat. Biotechnol. 17, 403-404.
44. PITTS, A.E., and COREY, D.R. (1998). Inhibition of human telomerase by 2′-O-methyl-RNA. Proc. Natl. Acad. Sci. U.S.A. 95, 11549-11554.
45. PLAYER, M.R., and TORRENCE, P.P. (1998). The 2-5A system: Modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol. Ther. 78, 55-113.
46. PLAYER, M.R., BARNARD, D.L., and TORRENCE, P.F. (1998). Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA. Proc. Natl. Acad. Sci. U.S.A. 95, 8874-8879.
47. RAYMOND, E., SUN, D., CHEN, S.F., WINDLE, B., and VON HOFF, D.D. (1996). Agents that target telomerase and telomeres. Curr. Opin. Biotechnol. 7, 583-591.
48. SILVA, J., CHANG, K., HANNON, G.J., and RIVAS, F.V. (2004). RNA-interference-based functional genomics in mammalian cells: Reverse genetics coming of age. Oncogene 23, 8401-8409.
49. SILVERMAN, R.H. (1997). 2-5A-dependent RNase L: A regulated endoribonuclease in the interferon system. In: Ribonucleases: Structures and Functions. G. D'Alessio and J.F. Riordan, eds. (Academic Press, San Diego, CA), pp. 515-551.
50. SONG, Q., and JONES, R.A. (1999). Use of silyl ethers as fluoride scavengers in RNA synthesis. Tetrahedron Lett. 40, 4653.
51. STEIN, C.A., and CHENG, Y.C. (1993). Antisense oligonucleotides as therapeutic agents: Is the bullet really magical? Science 261, 1004-1012.
52. STEIN, C.A., and COHEN, J.S. (1988). Oligodeoxynucleotides as inhibitors of gene expression: A review. Cancer Res. 48, 2659-2668.
53. STEWART, S.A., and WEINBERG, R.A. (2000). Telomerase and human tumorigenesis. Semin. Cancer Biol. 10, 399-406.
54. TORRENCE, P.F., MAITRA, R.K., LESIAK, K., KHAMNEI, S., ZHOU, A., and SILVERMAN, R.H. (1993). Targeting RNA for degradation with a (2′-5′)oligoadenylate-antisense chimera. Proc. Natl. Acad. Sci. U.S.A. 90, 1300-1304.
55. TORRENCE, P.E., XIAO, W., LI, G., CRAMER, H., PLAYER, M.R., and SILVERMAN, R.H. (1997). Recruiting the 2-5A system for antisense therapeutics. Antisense Nucleic Acid Drug. Dev. 7, 203-206.
56. WANG, E.S., WU, K., CHIN, A.C., CHEN-KIANG, S., PONGRACZ, K., GRYAZNOV, S., and MOORE, M.A. (2004). Telomerase inhibition with an oligonucleotide telomerase template antagonist: In vitro and in vivo studies in multiple myeloma and lymphoma. Blood 103, 258-266.
57. WINCOTT, F., DIRENZO, A., SHAFFER, C., GRIMM, S., TRACZ, D., WORKMAN, C., SWEEDLER, D., GONZALEZ, C., SCARINGE, S., and USMAN, N. (1995). Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucleic Acids Res. 23, 2677-2684.
58. XIAO, W., PLAYER, M.R., LI, G., ZHANG, W., LESIAK, K., and TORRENCE, P.P. (1996). Synthesis and characterization of composite nucleic acids containing 2′,5′-oligoriboadenylate linked to antisense DNA. Antisense Nucleic Acid Drug Dev. 6, 247-258.
59. ZHOU, A., KASSEL, B.A., and SILVERMAN, R.H. (1993). Expression cloning of 2-5A-dependent RNase: A uniquely regulated mediator of interferon action. Cell 72, 753-765.
60. ZON, G. (1988). Oligonucleotide analogues as potential chemotherapeutic agents. Pharm. Res. 5, 539-549.